Results for dementia with lewy bodies translation from English to Danish

dementia with lewy bodies.
demens med lewy- legemer

parkinson’s disease and dementia with lewy bodies
parkinsons sygdom og lewy body-demens

clinical studies in patients with dementia with lewy bodies
kliniske forsøg hos patienter med demens med lewy legemer

parkinsonism (including parkinson’s disease) and dementia with lewy bodies.
parkinsonisme (herinder parkinsons sygdom) og demens med lewy-legemer

to help differentiate probable dementia with lewy bodies from alzheimer’ s disease.
for at hjælpe med til at skelne mellem sandsynlig demens med lewy legemer og alzheimers sygdom.

· to help differentiate probable dementia with lewy bodies from alzheimer 's disease.
· for at hjælpe med til at skelne mellem sandsynlig demens med lewy legemer og

of dementia known as ` dementia with lewy bodies'from alzheimer 's disease.
demens, der kaldes " lewy body demens ", og alzheimers sygdom.

lewy body dementia
lewy body-demens

datscan is unable to discriminate between dementia with lewy bodies and parkinson 's disease dementia.
alzheimers sygdom.datscan er ikke i stand til at skelne mellem demens med lewy legemer og demens ved parkinsons sygdom.

datscan is used to help distinguish between a type of dementia known as ‘dementia with lewy bodies’ and alzheimer’s disease.
datscan benyttes til at skelne mellem en form for demens, der kaldes "lewy body-demens", og alzheimers sygdom.

changes in this area of the brain occur in: • parkinsonism (including parkinson’ s disease) and • dementia with lewy bodies.
forandringer i denne del af hjernen forekommer ved: • parkinsonisme (herinder parkinsons sygdom) og • demens med lewy- legemer

in dementia, the sensitivity of datscan in distinguishing dementia caused by lewy bodies from other types of dementia ranged from 75 to 80%.
i forhold til demens lå følsomheden af datscan til at skelne lewy body-demens fra andre typer demens på mellem 75 og 80 %.

in dementia, datscan has been studied in 288 patients who had been diagnosed with either dementia with lewy bodies or alzheimer’ s disease, as well as some other forms of dementia.
til demens er datscan undersøgt hos 288 patienter, der havde fået stillet diagnosen lewy body demens, alzheimers sygdom eller andre former for demens.

the values for the sensitivity of datscan to distinguish probable dementia caused by lewy bodies from other types of dementia ranged from 75.0 to 80.2%.
følsomheden af datscan til at skelne formodet lewy body demens fra andre typer demens lå mellem 75, 0 og 80, 2%.

physicians should weigh the risks versus the benefits when prescribing antipsychotics, including risperdal, to patients with parkinson’ s disease or dementia with lewy bodies (dlb).
risici og fordele bør afvejes nøje ved ordination af antipsykotika, herunder risperdal, til patienter med parkinsons sygdom eller lewy- body- demens; parkinsons sygdom kan forværres af risperidon.

physicians should weigh the risks versus the benefits when prescribing antipsychotics, including risperdal consta, to patients with parkinson’ s disease or dementia with lewy bodies (dlb).
tag sprøjten, og træk hylsteret af rekonstitutionskanylen uden at vride.

datscan is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. • to help differentiate probable dementia with lewy bodies from alzheimer’ s disease.
datscan er ikke i stand til at skelne mellem parkinsons sygdom, multipel systemisk atrofi og progressiv nukleær lammelse. • for at hjælpe med til at skelne mellem sandsynlig demens med lewy legemer og alzheimers sygdom.

invega should be used with caution in elderly patients with dementia with risk factors for stroke (see section 4.4) .
invega bør anvendes med forsigtighed til ældre patienter med demens og samtidig risiko for slagtilfælde (se pkt.4. 4) .

physicians should weigh the risks versus the benefits when prescribing invega to patients with parkinson’s disease or dementia with lewy bodies (dlb) since both groups may be at increased risk of neuroleptic malignant syndrome as well as having an increased sensitivity to antipsychotics.
risici og fordele bør afvejes ved ordination af invega til patienter med parkinsons sygdom eller demens med lewy-legemer, eftersom begge grupper kan have øget risiko for malignt neuroleptikasyndrom samt øget sensitivitet for antipsykotika.

7.3 the eesc welcomes the commitment to the provision of special training for health and care staff, and family members of those with dementia, with its holistic approach to care.
7.3 eØsu anerkender indsatsen for at tilbyde særlig uddannelse af sundheds- og plejepersonale, familiemedlemmer og pårørende til demente sammen med en helhedsorienteret tilgang til pleje.